DA Davidson raised the firm’s price target on Paysign to $4.50 from $4 and keeps a Buy rating on the shares. The company’s Q4 results saw “impressive upside” as revenue in the Plasma Donor Compensation segment increased by 19% from last year, the analyst tells investors in a research note. Paysign management also relayed they were able to take advantage of disruptions in the industry and added 10 programs in Q1, the firm stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
